MX390417B - Tratamiento de enfermedades colestasicas intrahepaticas. - Google Patents

Tratamiento de enfermedades colestasicas intrahepaticas.

Info

Publication number
MX390417B
MX390417B MX2018014915A MX2018014915A MX390417B MX 390417 B MX390417 B MX 390417B MX 2018014915 A MX2018014915 A MX 2018014915A MX 2018014915 A MX2018014915 A MX 2018014915A MX 390417 B MX390417 B MX 390417B
Authority
MX
Mexico
Prior art keywords
treatment
intrahepatic cholestatic
cholestatic diseases
diseases
intrahepatic
Prior art date
Application number
MX2018014915A
Other languages
English (en)
Spanish (es)
Other versions
MX2018014915A (es
Inventor
Charles A Mcwherter
Pol Boudes
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2018014915A publication Critical patent/MX2018014915A/es
Publication of MX390417B publication Critical patent/MX390417B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018014915A 2016-05-31 2017-04-26 Tratamiento de enfermedades colestasicas intrahepaticas. MX390417B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
MX2018014915A MX2018014915A (es) 2019-04-24
MX390417B true MX390417B (es) 2025-03-20

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014915A MX390417B (es) 2016-05-31 2017-04-26 Tratamiento de enfermedades colestasicas intrahepaticas.

Country Status (27)

Country Link
US (5) US10272058B2 (https=)
EP (1) EP3463328B1 (https=)
JP (1) JP7079735B2 (https=)
KR (1) KR102408288B1 (https=)
CN (2) CN109195594A (https=)
AU (1) AU2017274293B2 (https=)
BR (1) BR112018074147A2 (https=)
CA (1) CA3024155C (https=)
CY (1) CY1125465T1 (https=)
DK (1) DK3463328T3 (https=)
ES (1) ES2921230T3 (https=)
HR (1) HRP20220903T1 (https=)
HU (1) HUE059838T2 (https=)
IL (1) IL263372B2 (https=)
LT (1) LT3463328T (https=)
MX (1) MX390417B (https=)
NZ (1) NZ748721A (https=)
PL (1) PL3463328T3 (https=)
PT (1) PT3463328T (https=)
RS (1) RS63345B1 (https=)
RU (1) RU2765460C2 (https=)
SG (1) SG11201810123SA (https=)
SI (1) SI3463328T1 (https=)
SM (1) SMT202200471T1 (https=)
UA (1) UA122719C2 (https=)
WO (1) WO2017209865A1 (https=)
ZA (1) ZA201808360B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2020102337A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash
FI4225291T3 (fi) * 2021-02-01 2024-06-03 Cymabay Therapeutics Inc Kolangiopatioiden hoito seladelpaarilla
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112016023269A8 (pt) 2014-04-11 2021-06-29 Cymabay Therapeutics Inc uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
EA201790091A1 (ru) 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SMT202200171T1 (it) 2017-09-26 2022-05-12 Cymabay Therapeutics Inc Trattamento del prurito colestatico con seladelpar
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
WO2020102337A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
US20200061006A1 (en) 2020-02-27
BR112018074147A2 (pt) 2019-03-06
US10272058B2 (en) 2019-04-30
KR20190015363A (ko) 2019-02-13
EP3463328B1 (en) 2022-06-15
DK3463328T3 (da) 2022-07-04
CA3024155A1 (en) 2017-12-07
SI3463328T1 (sl) 2022-08-31
RU2018146504A3 (https=) 2020-07-27
MX2018014915A (es) 2019-04-24
KR102408288B1 (ko) 2022-06-10
IL263372A (en) 2018-12-31
JP7079735B2 (ja) 2022-06-02
US20210220305A1 (en) 2021-07-22
RS63345B1 (sr) 2022-07-29
AU2017274293B2 (en) 2022-03-31
US10478411B2 (en) 2019-11-19
RU2765460C2 (ru) 2022-01-31
WO2017209865A1 (en) 2017-12-07
CA3024155C (en) 2023-10-10
LT3463328T (lt) 2022-08-10
PT3463328T (pt) 2022-07-07
RU2018146504A (ru) 2020-07-09
SG11201810123SA (en) 2018-12-28
NZ748721A (en) 2022-04-29
SMT202200471T1 (it) 2023-01-13
CN109195594A (zh) 2019-01-11
AU2017274293A1 (en) 2018-12-13
PL3463328T3 (pl) 2022-10-03
JP2019518022A (ja) 2019-06-27
US20190255004A1 (en) 2019-08-22
ZA201808360B (en) 2020-02-26
US11000494B2 (en) 2021-05-11
CY1125465T1 (el) 2025-05-09
US20170340589A1 (en) 2017-11-30
US20210000774A1 (en) 2021-01-07
HUE059838T2 (hu) 2023-01-28
CN121466055A (zh) 2026-02-06
US11596614B2 (en) 2023-03-07
IL263372B2 (en) 2023-06-01
ES2921230T3 (es) 2022-08-22
EP3463328A1 (en) 2019-04-10
UA122719C2 (uk) 2020-12-28
US10813895B2 (en) 2020-10-27
HRP20220903T1 (hr) 2022-10-14

Similar Documents

Publication Publication Date Title
MX2020007273A (es) Tratamiento del prurito colestasico.
MX369921B (es) Tratamiento de la hgna y ehna.
EP3813808A4 (en) Methods of treating substance abuse
PL3554631T3 (pl) Leczenie pacjentów polami ttfields ze zoptymalizowanymi pozycjami elektrod z wykorzystaniem odkształcalnych matryc
KR102199943B9 (ko) 의료용 자극 장치
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX2016012203A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
MX390417B (es) Tratamiento de enfermedades colestasicas intrahepaticas.
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
DK3360508T3 (da) Hjælpeanordning til dental behandling
PT3458052T (pt) Tratamento combinado do cancro
LT3458610T (lt) Krūties vėžio terapinis gydymas, remiantis c-maf būkle
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
LT3576740T (lt) Vėžio gydymas
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985
IL259381B (en) Mirabegron for the treatment of retinal diseases
ITUA20162868A1 (it) Apparato di trattamento di una scocca
PL3302499T3 (pl) Leczenie chorób mitochondrialnych
LT3322438T (lt) Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych